Entrada Therapeutics, Inc. (TRDA) · Nov 5, 2026 · Earnings
Miss — EPS loss $0.94 vs ~$0.98 consensus; revenue $0.9M vs ~$2.13M consensus
Entrada earnings beat the EPS estimate but collaboration revenue missed sharply. The bigger story: clinical catalysts remain on track and cash now extends into Q4 2027.
Entrada is a clinical-stage biotech advancing multiple Duchenne muscular dystrophy programs while its partnered Vertex program targets myotonic dystrophy; the near-term story is a dense run of clinical readouts rather than commercial revenue. That setup was already established before this release, including the expected ELEVATE-44-201 and ELEVATE-45-201 milestones and a cash runway previously projected into Q3 2027.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Collaboration revenue (Income Statement) | $0.9M (-43.9%) | $1.6M | ~$2.13M |
| Net loss per share (Income Statement) | $(0.94) | $(1.06) | ~$(0.98) |
| R&D expense (Income Statement) | $32.4M (-15.6%) | $38.4M | |
| Cash and marketable securities (Cash Position) | $193.0M (-34.7% vs. Dec. 2025) | $295.7M |
The quarterly financial result is a revenue miss, despite a modest EPS beat. The $0.94 per-share loss was slightly better than the published consensus near $0.98, but collaboration revenue of only $0.9 million was well below the roughly $2.13 million expectation. That revenue line is milestone-driven and volatile, so the miss says less about underlying drug demand than it would for a commercial company, but it still leaves the quarter below the financial bar. The filing reports that collaboration revenue was $905,000 in the quarter, versus $1.614 million a year earlier.
The operating profile remains controlled, but the company is still consuming capital heavily. R&D spending fell to $32.4 million from $38.4 million, while G&A was essentially flat at $10.2 million versus $10.3 million. The lower R&D spend reflects reduced preclinical and facility costs rather than a disclosed acceleration in clinical productivity.
The balance-sheet update is modestly better than the prior funding picture. Cash, cash equivalents and marketable securities fell to $193.0 million from $295.7 million at year-end, but management now expects funding into Q4 2027, one quarter later than the runway described in the prior update. 〔0〕 That extends the time available to reach upcoming clinical readouts without an immediately disclosed financing need, although the company remains dependent on future clinical progress and eventual additional capital.
The pipeline update is mostly confirmation, not a new clinical inflection point. The positive ENTR-601-45 Cohort 1 safety data and the decision to advance ENTR-601-44 to its highest planned dose were announced in October, so this filing largely carries those developments forward. The new practical takeaway is that Entrada still points to four clinical readouts through the first half of 2027, with longer-duration functional data now the key test of whether early safety signals translate into meaningful efficacy. 〔1〕
Bottom line: This is a mixed quarter: the EPS loss was slightly better than expected and the runway improved, but collaboration revenue missed badly. The business story is still driven by upcoming DMD and DM1 data, not by this quarter’s financials, so the filing modestly complicates rather than overturns the clinical narrative.
ELEVATE-44-201 Cohort 1 open-label data by year-end 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!